Our 5th Annual MarketsandMarkets Next Gen Immuno-Oncology Conference to be held on 23rd-24th, June 2022, in Boston, would address the challenges and future directions in IO research. The congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the latest updates in development of ADC’s, Bispecific Antibodies, Cellular Therapy and Immune Checkpoint Inhibitors.
This congress would also focus on various combination strategies, pre-clinical and translational immune-oncology developments, updates in cellular and viral therapies, vaccines development and personalized immunotherapy. Keynote presentations, Brainstorming Panel Discussions and Case studies will give the stakeholders an opportunity to discuss and understand the issues faced and come up with solutions.
With more than 20 speakers across the world from pharma, bio-pharma and biotech companies, the congress will discuss the latest updates in development of ADC’s, Monoclonal Antibodies, Bispecific Antibodies, Immune Checkpoint Inhibitors and Cellular Therapy
Program Director, Biorepositories and Biospecimen Research Branch (BBRB), , NIH
CEO, Kibur Medical Inc.
CSO, Asha Therapeutics
Chief Scientific Officer, Proteome Sciences PLC
Co-Founder, Attivare Therapeutics
Principal Researcher, Argentina National Council of Scientific Research
CEO, Founder, Asha Therapeutics
Senior Director, Oncology & Precision Medicine , Qiagen
Senior Scientist , Amgen
Assistant Professor, Oncology Roswell Park Comprehensive Cancer Center
Chief Scientific Officer, Janux Therapeutics
President & CEO, Triumvira Immunologics
Hyatt Regency Boston/Cambridge